## DOCKET NO: ISIS0055-100 (RTS-0236)

**PATENT** 

## IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Please amend claim 1 and cancel claims 20-24, 26-28, 30, and 32-40 as indicated below.

- 1. (currently amended) A <u>modified</u> compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding EIF2C1 (SEQ ID NO:3), wherein said compound specifically hybridizes with said nucleic acid molecule encoding EIF2C1 and inhibits the expression of EIF2C1 by at least 42%.
- 2. (original) The compound of claim 1 which is an antisense oligonucleotide.
- 3. (canceled).
- 4. (original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
- 5. (original) The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothicate linkage.
- 6. (original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
- 7. (original) The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
- 8. (original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

## DOCKET NO: ISIS0055-100 (RTS-0236)

PATENT

- 9. (original) The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.
- 10. (original) The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
- 11. (original) A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding EIF2C1.
- 12. (original) A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
- 13. (original) The composition of claim 12 further comprising a colloidal dispersion system.
- 14. (original) The composition of claim 12 wherein the compound is an antisense oligonucleotide.
- 15. (previously presented) A method of inhibiting the expression of EIF2C1 in cells or tissues comprising contacting cells or tissues in vitro with the compound of claim 1 so that expression of EIF2C1 is inhibited.
- 16-28. (canceled).
- 29. (previously presented) The compound of claim 1 wherein said compound inhibits EIF2C1 expression by at least 60%.
- 30. (canceled).

## DOCKET NO: ISIS0055-100 (RTS-0236)

**PATENT** 

(previously presented) The compound of claim 29 wherein said compound inhibits 31. EIF2C1 expression by at least 80%.

32-40. (cancelled).